Post-earnings recap
Reported
Mon, Aug 10, 2009
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Arrowhead Pharmaceuticals reported a loss per share of $0.06, but the stock rose by 4.63% following the earnings announcement. The increase in stock price may reflect investor optimism despite the lack of revenue data and management commentary. The market's reaction suggests that investors are looking beyond the immediate financials.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.06 | N/A | — |
| Revenue | — | N/A | — |
No transcript is on record, so the analysis is based solely on numerical results.